Ash reduction of corn stover by mild hydrothermal preprocessing

Lignocellulosic biomass such as corn stover can contain high ash content, which may act as an inhibitor in downstream conversion processes. Most of the structural ash in biomass is located in the cross-linked structure of lignin, which is mildly reactive in basic solutions. Four organic acids (formic, oxalic, tartaric, and citric) were evaluated for effectiveness in ash reduction, with limited success. Because of sodium citrate’s chelating and basic characteristics, it is effective in ash removal. More than 75 % of structural and 85 % of whole ash was removed from the biomass by treatment with 0.1 g of sodium citrate per gram of biomass at 130 °C and 2.7 bar. FTIR, fiber analysis, and chemical analyses show that cellulose and hemicellulose were unaffected by the treatment. ICP–AES showed that all inorganics measured were reduced within the biomass feedstock, except sodium due to the addition of Na through the treatment. Sodium citrate addition to the preconversion process of corn stover is an effective way to reduced physiological ash content of the feedstock without negatively impacting carbohydrate and lignin content

MANAGEMENT DELLO SCHWANNOMA INTRALABIRINTICO

Lo schwannoma intralabirintico (SIL) è un raro tumore benigno (prevalenza 0.1-0.4%) che origina dalle cellule di Schwann perineurali del nervo cocleovestibolare prossimale al labirinto membranoso (coclea, vestibolo o canali semicircolari). E’ stato descritto per la prima volta da Meter nel 1917. I sintomi clinici di esordio includono ipoacusia neurosensoriale monolaterale progressiva (95%) e in alcuni casi improvvisa o fluttuante, acufeni (51%), disequilibrio (35%), vertigine (22%), fullness (2%). Alla risonanza magnetica (RM) il tumore si presenta come una massa circoscritta, ipointensa nelle sequenze T2-pesate e con un forte enhancement dopo somministrazione di gadolinio nelle immagini T1-pesate. Lo SIL si pone in diagnosi differenziale con M. di Meniere o neurite vestibolare. La mancanza di sintomi specifici e il lento pattern di crescita spiega la diagnosi tardiva. Oggigiorno la RM permette una diagnosi sempre più precoce e l’ adozione di un appropriato protocollo terapeutico

INQUADRAMENTO CLINICO E MANAGEMENT DELLO SCHWANNOMA ESCLUSIVAMENTE INTRALABIRINTICO

Lo schwannoma intralabirintico (SIL) è un raro tumore benigno (prevalenza 0.1-0.4%) che origina dalle cellule di Schwann situate a ridosso della giunzione cito-neurale dell’VIII n.c. I sintomi clinici includono ipoacusia neurosensoriale monolaterale progressiva (95%), acufeni (51%), disequilibrio (35%), vertigine (22%), fullness (2%). Alla risonanza magnetica (RM) il tumore si presenta come una massa circoscritta, iperintensa in T1, ipointensa in T2 e con enhancement dopo gadolinio nelle immagini T1-pesate. Il management prevede in prima istanza osservazioni seriali con RM “wait and scan approach”. La chirurgia, considerando le complicanze descritte quali anacusia (100%), paralisi VII n.c. (4%), fistola liquorale (5.4%), meningite (1.8%), è riservata a casi limitati e dipende da: età, condizioni generali del paziente, sede e dimensioni del tumore ed è consigliabile in caso di un pattern di crescita invasivo e presenza di sintomi vertiginosi non responsivi al trattamento medico

Neutralization of Botulinum Neurotoxin by a Human Monoclonal Antibody Specific for the Catalytic Light Chain

Background: Botulinum neurotoxins (BoNT) are a family of category A select bioterror agents and the most potent biological toxins known. Cloned antibody therapeutics hold considerable promise as BoNT therapeutics, but the therapeutic utility of antibodies that bind the BoNT light chain domain (LC), a metalloprotease that functions in the cytosol of cholinergic neurons, has not been thoroughly explored. Methods and Findings: We used an optimized hybridoma method to clone a fully human antibody specific for the LC of serotype A BoNT (BoNT/A). The 4LCA antibody demonstrated potent in vivo neutralization when administered alone and collaborated with an antibody specific for the HC. In Neuro-2a neuroblastoma cells, the 4LCA antibody prevented the cleavage of the BoNT/A proteolytic target, SNAP-25. Unlike an antibody specific for the HC, the 4LCA antibody did not block entry of BoNT/A into cultured cells. Instead, it was taken up into synaptic vesicles along with BoNT/A. The 4LCA antibody also directly inhibited BoNT/A catalytic activity in vitro. Conclusions: An antibody specific for the BoNT/A LC can potently inhibit BoNT/A in vivo and in vitro, using mechanisms not previously associated with BoNT-neutralizing antibodies. Antibodies specific for BoNT LC may be valuable components o

The Tumor-Immune Microenvironment and Response to Radiation Therapy

Chemotherapy and radiation therapy (RT) are standard therapeutic modalities for patients with cancer, including breast cancer. Historic studies examining tissue and cellular responses to RT have predominantly focused on damage caused to proliferating malignant cells leading to their death. However, there is increasing evidence that RT also leads to significant alterations in the tumor microenvironment, particularly with respect to effects on immune cells infiltrating tumors. This review focuses on tumor-associated immune cell responses following RT and discusses how immune responses may be modified to enhance durability and efficacy of RT

Cortical injury in multiple sclerosis; the role of the immune system

The easily identifiable, ubiquitous demyelination and neuronal damage that occurs within the cerebral white matter of patients with multiple sclerosis (MS) has been the subject of extensive study. Accordingly, MS has historically been described as a disease of the white matter. Recently, the cerebral cortex (gray matter) of patients with MS has been recognized as an additional and major site of disease pathogenesis. This acknowledgement of cortical tissue damage is due, in part, to more powerful MRI that allows detection of such injury and to focused neuropathology-based investigations. Cortical tissue damage has been associated with inflammation that is less pronounced to that which is associated with damage in the white matter. There is, however, emerging evidence that suggests cortical damage can be closely associated with robust inflammation not only in the parenchyma, but also in the neighboring meninges. This manuscript will highlight the current knowledge of inflammation associated with cortical tissue injury. Historical literature along with contemporary work that focuses on both the absence and presence of inflammation in the cerebral cortex and in the cerebral meninges will be reviewed

T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers

Introduction: Lymphocyte infiltration (LI) is often seen in breast cancer but its importance remains controversial. A positive correlation of human epidermal growth factor receptor 2 (HER2) amplification and LI has been described, which was associated with a more favorable outcome. However, specific lymphocytes might also promote tumor progression by shifting the cytokine milieu in the tumor. Methods: Affymetrix HG-U133A microarray data of 1,781 primary breast cancer samples from 12 datasets were included. The correlation of immune system-related metagenes with different immune cells, clinical parameters, and survival was analyzed. Results: A large cluster of nearly 600 genes with functions in immune cells was consistently obtained in all datasets. Seven robust metagenes from this cluster can act as surrogate markers for the amount of different immune cell types in the breast cancer sample. An IgG metagene as a marker for B cells had no significant prognostic value. In contrast, a strong positive prognostic value for the T-cell surrogate marker (lymphocyte-specific kinase (LCK) metagene) was observed among all estrogen receptor (ER)-negative tumors and those ER-positive tumors with a HER2 overexpression. Moreover ER-negative tumors with high expression of both IgG and LCK metagenes seem to respond better to neoadjuvant chemotherapy. Conclusions: Precise definitions of the specific subtypes of immune cells in the tumor can be accomplished from microarray data. These surrogate markers define subgroups of tumors with different prognosis. Importantly, all known prognostic gene signatures uniformly assign poor prognosis to all ER-negative tumors. In contrast, the LCK metagene actually separates the ER-negative group into better or worse prognosis

Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer

International audienceMale breast cancer (MBC) is a poorly characterized disease because of its rarity. Clinical management is based on results obtained from randomized trials conducted in women notwithstanding data in the literature suggesting relevant gender-associated differences in terms of biological and clinical behavior. However, a genome-wide characterization of MBC on a transcriptional level is lacking. In this study, gene expression profiles of 37 estrogen receptor positive (ER+) MBC specimens were compared to that of 53 ER+ Female Breast Cancer (FBC) samples similar for clinical and patho-biological features. Almost 1000 genes were found differentially expressed (FDR < 1%) between female and male patients and biological interpretation highlighted a gender-associated modulation of key biological processes ranging from energy metabolism to regulation of translation and matrix remodeling as well as immune system recruitment. Moreover, an analysis of genes correlated to steroid receptors and ERBB2 suggested a prominent role for the androgen receptor in MBC with a minor relevance for progesterone receptor and ERBB2, although, similarly to FBC, a genomic amplification could be observed. Our findings support the idea that breast cancer is a quite different disease in male and female patients and the underlying gender-related biological differences are likely to have clinical implications connected with different susceptibility to treatment